# MT-601

Source: https://onco.cc/drugs/mt-601/  
OnCo record `mt-601` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MT-601 is an experimental autologous multi-antigen recognizing T cell therapy, not genetically modified from Marker Therapeutics, in phase 1 trials for relapsed lymphoma and pancreatic cancer.

## Summary

MT-601 is an autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified from Marker Therapeutics. Multi-antigen specific CD4+ and CD8+ T cells that recognise six tumour antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), designed to recognise and kill tumours without genetic modification. Its furthest stage is phase 1, for relapsed lymphoma (including after or ineligible for anti-CD19 CAR-T) and pancreatic cancer. ClinicalTrials.gov registers it in 2 studies linked below. Lymphoma study NCT05798897 recruiting (phase 1); pancreatic study NCT06549751 registered, not yet recruiting (phase 1). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: MT-601
- Modality: Autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified
- Mechanism: Multi-antigen specific CD4+ and CD8+ T cells that recognise six tumour antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), designed to recognise and kill tumours without genetic modification.

## Sources

- Marker Therapeutics: markertherapeutics.com: https://markertherapeutics.com/
- Marker Therapeutics: markertherapeutics.com: https://markertherapeutics.com/
- Marker Therapeutics: markertherapeutics.com: https://markertherapeutics.com/
- Marker Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05798897
- ClinicalTrials.gov: trials of MT-601: https://clinicaltrials.gov/search?intr=MT-601

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [BIRC5](https://onco.cc/targets/birc5/), [CTAG1B](https://onco.cc/targets/ctag1b/), [MAGE-A4](https://onco.cc/targets/mage-a4/), [PRAME](https://onco.cc/targets/prame/), [SSX2](https://onco.cc/targets/ssx2/), [WT1](https://onco.cc/targets/wt1/)
- companies: [Marker Therapeutics](https://onco.cc/companies/marker-therapeutics/)
- trials: [MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06549751/), [Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma](https://onco.cc/trials/nct05798897/)

---
JSON: https://onco.cc/api/v1/entities/mt-601.json